Clinical Trial 24244

• Overview

  Study Title:

  A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

  Summary:

  The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma

  Objective:

  Phase 2 Primary Objective: * To evaluate OR of two different dose levels of pumitamig in combination with chemotherapy in participants with GC/GEJC/EAC. Secondary Objectives: * To evaluate the efficacy of two different dose levels of pumitamig in combination with chemotherapy in participants with GC/GEJC/EAC. * To inform the dose of pumitamig to continue in Phase 3 of the study. Phase 3 Primary Objectives: * To compare PFS of pumitamig in combination with chemotherapy vs nivolumab in combination with chemotherapy in participants with GC/GEJC/EAC. * To compare OS of pumitamig in combination with chemotherapy vs nivolumab in combination with chemotherapy in participants with GC/GEJC/EAC. Secondary Objective: * To evaluate the efficacy of pumitamig in combination with chemotherapy vs nivolumab in combination with chemotherapy in participants with GC/GEJC/EAC.

• Treatments

  Therapies:

  Bispecific antibody targeting PD-L1 and VEGF-A; Chemotherapy (NOS); Immune Checkpoint Inhibitors; Immunotherapy

  Medications:

  5-fluorouracil (); BMS-936558 (Nivolumab); Nivolumab (Opdivo); Oxaliplatin (); Pumitamig (); Xeloda (capecitabine); capecitabine (); eloxatin (Oxaliplatin); leucovorin ()

• Inclusion Criteria

  Key Inclusion Criteria:
  • Participants must be previously untreated with systemic treatment for advanced/metastatic disease, histologically or cytologically confirmed advanced or metastatic gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJC) or distal esophageal adenocarcinoma (EAC). GEJ involvement can be confirmed via biopsy, endoscopy, or imaging.
  • Participants must have a documented programmed cell death-(ligand)1 (PD-L1) ≥ 1 or > Participants must have documented human epidermal growth factor receptor 2 (HER2)-negative cancer, as determined according to local guidelines.
  • Participants must have measurable disease as defined by RECIST v1.1.

• Exclusion Criteria

  Key Exclusion Criteria:
  • Participants must not have untreated known central nervous system (CNS) metastases.
  • Participants must not have significant cardiovascular disease, such as myocardial infarction, unstable angina, arterial thrombosis, cerebrovascular accident within 6 months prior to randomization, uncontrolled hypertension (≥ 160 systolic, ≥ 100 diastolic mm Hg) despite optimal medical management, or congenital long QT syndrome.
  • Participants must not have evidence of major coagulation disorders (eg, hemophilia).
  • Participants must not have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism within 3 months prior to randomization, unless the participant has been fully treated (eg, inferior vena cava filter placed) and/or adequately anticoagulated on a stable dose.
  • Participants must not have a history of abdominal fistula or gastrointestinal (GI) perforation within 6 months of randomization.
  • Participants must not have had major surgery, open biopsy, or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study intervention.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.